Orforglipron
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Oral non-peptide small-molecule GLP-1 receptor agonist (Eli Lilly); investigational daily oral agent for obesity and type 2 diabetes.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | LY3502970 |
| Category | Non-Peptide GLP-1 Receptor Agonist (Small Molecule) |
| Sequence | N/A — Orforglipron is NOT a peptide. It is a small-molecule organic compound. |
| Molecular Weight | ~632 Da |
| Molecular Formula | C34H36F3N3O3S (approximate) |
| PubChem CID | 163452725 |
| Administration | Oral, once daily |
| Typical Dose Range | 12-45 mg once daily (Phase 2 dose range) |
| Half-Life | ~29 hours |
| Storage | Room temperature (investigational) |
| FDA Status | Investigational — Phase 3 (ATTAIN program for obesity and T2D) |
| WADA Status | Not listed (investigational) |
CRITICAL CLASSIFICATION NOTE: Orforglipron is explicitly NOT a peptide. It is a small-molecule, non-peptide GLP-1 receptor agonist. It is included in this vault because:
- It activates the same GLP-1 receptor (GLP1R, UniProt P43220) targeted by peptide-based GLP-1 RAs (semaglutide, exenatide, dulaglutide, liraglutide)
- Practitioners using injectable GLP-1 peptides MUST understand the oral non-peptide alternatives their patients will ask about
- If orforglipron achieves Phase 3 success, it could fundamentally shift the injectable-vs-oral treatment paradigm for obesity and T2D
- This parallels the vault's inclusion of other non-peptide compounds like MK-677 (non-peptide GH secretagogue), Relugolix (non-peptide GnRH antagonist), and Elagolix (non-peptide GnRH antagonist) that act on peptide-relevant receptor systems
Mechanism of Action
Orforglipron is a small-molecule agonist of the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Unlike all currently approved GLP-1 RAs, which are either peptide analogs (semaglutide, liraglutide, exenatide, dulaglutide) or modified peptides requiring injection, orforglipron is a fully synthetic non-peptide compound that can be absorbed orally without requiring the permeation enhancer (SNAC) needed by oral semaglutide (Rybelsus).
Orforglipron binds to the GLP-1R at a site partially overlapping with the orthosteric peptide-binding site but with a distinct binding mode that explains its unique pharmacological properties. Upon binding, orforglipron activates the same downstream signaling cascades as peptide GLP-1 RAs: Gs-protein coupling leading to cAMP production, PKA and Epac2 activation, and beta-arrestin recruitment. This produces the canonical GLP-1R effects:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon secretion from alpha cells (glucose-dependent)
- Delayed gastric emptying reducing postprandial glucose excursions
- Central appetite suppression via hypothalamic and brainstem GLP-1R activation
- Potential cardioprotection through vascular and cardiac GLP-1R signaling
The key pharmacological advantages of the small-molecule approach include:
- Oral bioavailability — No injection required; no SNAC/permeation enhancer needed (unlike oral semaglutide)
- Chemical stability — Not susceptible to peptidase degradation; stable at room temperature
- Manufacturing simplicity — Small-molecule synthesis is scalable and potentially less expensive than peptide manufacturing
- 29-hour half-life — Supports once-daily dosing with stable plasma concentrations
Key Research Areas
- Obesity/Weight Loss — Phase 2 NEJM trial showed 9.4-14.7% body weight loss at 36 weeks; comparable to injectable GLP-1 RAs (PMID: 37351564)
- Type 2 Diabetes — Phase 2 Lancet trial demonstrated HbA1c reductions up to -2.10% and weight loss up to -10.1 kg; superior to dulaglutide 1.5 mg (PMID: 37369232)
- Oral GLP-1 RA Development — First non-peptide oral GLP-1 RA to demonstrate clinical efficacy comparable to injectable agents
- Phase 3 Program (ATTAIN) — Multiple Phase 3 trials underway for obesity and T2D; results expected 2025-2026
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 4+ | Phase 1a/1b, Phase 2 (obesity), Phase 2 (T2D), Phase 3 ongoing |
| Human observational | 0 | Investigational — no real-world data |
| Animal in vivo | 5+ | Preclinical pharmacology and toxicology |
| In vitro | 5+ | GLP-1R binding, signaling characterization |
| Systematic reviews | 2+ | Meta-analyses of Phase 2 data |
Clinical Applications
- Weight Management — Investigational; Phase 2 showed ~15% weight loss at highest dose
- Type 2 Diabetes — Investigational; superior glycemic control vs. dulaglutide
- Metabolic Syndrome — Broad cardiometabolic improvements observed
Protocols Using This Peptide
No current vault protocols include orforglipron as it remains investigational and is a non-peptide compound. However, practitioners following the Weight Loss Protocol or Metabolic Reset Protocol should understand orforglipron as a potential future oral alternative to injectable GLP-1 RAs.
Ageless Peps Products
Orforglipron is an investigational drug (Eli Lilly) and is NOT sold by Ageless Peps. As a non-peptide compound, it would not fall within Ageless Peps' peptide product category even if approved.
Dosing Reference
Clinical Trial Dosing (Investigational)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| Oral (Obesity) | 12, 24, 36, 45 mg | Once daily | 36 weeks (Phase 2) | PMID 37351564 |
| Oral (T2D) | 3, 12, 24, 36, 45 mg | Once daily | 26 weeks (Phase 2) | PMID 37369232 |
Dose Escalation
Phase 2 trials used dose escalation over the first 12-29 days to mitigate GI adverse effects. The optimal dose for weight loss appears to be 36-45 mg daily. The optimal dose for T2D appears to be 12 mg or higher.
Cycling
Not applicable (chronic therapy in clinical trials).
Contraindications & Safety
- Contraindications (from trials): History of MTC, MEN2 (precautionary GLP-1 RA class label)
- Common side effects: Nausea (dose-dependent, most common), vomiting, diarrhea, constipation, decreased appetite — GI event rates (44-70%) similar to injectable GLP-1 RAs
- Drug interactions: Delayed gastric emptying may affect oral medication absorption (class effect)
- Pregnancy/nursing: Not studied; expected contraindication
- Special populations: Limited data; Phase 1 PK studies in hepatic/renal impairment ongoing
- Notable: No cases of pancreatitis or medullary thyroid carcinoma in Phase 2 trials
Why Practitioners Must Understand Orforglipron
The emergence of orforglipron represents a potential paradigm shift in metabolic peptide therapy:
- Patient demand for oral alternatives — Many patients prefer pills over injections; orforglipron could capture significant market share from injectable GLP-1 peptides
- Accessibility — Oral administration removes barriers of injection training, needle disposal, and cold-chain storage
- Pricing competition — Small-molecule manufacturing is potentially cheaper than peptide production, which could impact pricing across the GLP-1 RA category
- Differentiation opportunity for injectable peptides — If oral non-peptide GLP-1 RAs achieve comparable efficacy, injectable peptide therapists must articulate the unique value of their modality (e.g., multi-peptide stacking, dose flexibility, combination protocols)
Competitive Landscape
| Agent | Type | Route | Key Differentiator |
|---|---|---|---|
| Semaglutide | Peptide GLP-1 RA | SubQ or Oral (SNAC) | Gold standard; 15-17% weight loss |
| Tirzepatide | Peptide GIP/GLP-1 RA | SubQ | 20%+ weight loss; dual mechanism |
| Exenatide | Peptide GLP-1 RA | SubQ | First-in-class; moderate efficacy |
| Dulaglutide | Fusion protein GLP-1 RA | SubQ | CV benefit (REWIND); user-friendly pen |
| Orforglipron | Non-peptide GLP-1 RA | Oral (no SNAC) | First oral non-peptide; ~15% weight loss; daily pill |
Related Research
| Identifier | Title | Year | Study Type |
|---|---|---|---|
| PMID 37351564 | Daily oral GLP-1 receptor agonist orforglipron for adults with obesity | 2023 | RCT (Phase 2) |
| PMID 37369232 | Efficacy and safety of oral orforglipron in patients with type 2 diabetes | 2023 | RCT (Phase 2) |
| DOI-10-1056-NEJMoa2511774 – ATTAIN-1 Orforglipron Obesity | Orforglipron for Obesity (ATTAIN-1, Phase 3, n=3,127) | 2025 | RCT (Phase 3) |
ATTAIN-1 (Phase 3) — November 2025 NEJM
Wharton S et al., N Engl J Med 2025;393(19):1889-1901. doi: 10.1056/NEJMoa2511774.
| Dose | Mean weight loss at 72 weeks |
|---|---|
| Orforglipron 36 mg daily | -14.6% |
| Orforglipron 24 mg daily | -12.8% |
| Orforglipron 12 mg daily | -8.2% |
| Placebo | -2.0% |
Clinical significance: First oral non-peptide GLP-1 agonist to achieve Phase 3 efficacy within the range of injectable semaglutide 2.4 mg (STEP 1: -14.9%). No food/water/timing restrictions (unlike oral peptide semaglutide / Rybelsus). Manufacturing scalability via chemical synthesis may substantially expand access. FDA NDA filed; approval status pending — verify FDA.gov at time of reference.
References
- PMID 37351564 — Phase 2 obesity trial (NEJM 2023)
- PMID 37369232 — Phase 2 T2D dose-response trial (Lancet 2023)
- DOI 10.1056/NEJMoa2511774 — ATTAIN-1 Phase 3 obesity trial (NEJM 2025)
Related
- Peptide Index
- Condition Index
- Protocol Index
- Semaglutide
- Tirzepatide
- Exenatide
- Dulaglutide
- GLP-1 (Native)
#metabolic #investigational #not-sold #oral